AUTHORS
Chiara Adina Hummel, MD, Sami Sebastian Khaznadar, MD, MSc2, Zachary Hunzeker, MD3, James Hill, MD4, Ruitao Lin, PhD5, Karmila Murphy, NP-C6, Amy A. Ayers7, Jared Henderson, PhD8, Tania Patricia Sainz, BS9, Christopher R. Flowers Jr, MD, MS10, Mark P Hamilton, MD11, Michael Green, PhD12, Francisco Vega Sr, MD PHD13, Anath Christopher Lionel, MD, PhD14, Dai Chihara, MD, PhD15
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Epidemiological studies have demonstrated a nearly fivefold increased bidirectional risk between B-cell lymphomas (BCL) and T-cell lymphomas (TCL). However, the underlying mechanisms and risk factors for BCL and TCL diagnoses remain poorly understood. Improved characterization of this population may provide insight into shared risk factors and mechanisms of lymphomagenesis.
Methods: We performed a retrospective single-center study of 112 adult patients with dual BCL and TCL diagnoses from separate biopsy specimens at MD Anderson Cancer Center between January 2013 to May 2026. Patients with composite BCL and TCL in the same specimen were excluded. Demographic and clinical variables, including lymphoma subtype and temporal sequence, other non-lymphoid malignancies (NLMs), autoimmune comorbidities, family history, and viral serologies, were collected. T-cell clonality was assessed by PCR-based gene analysis of T-cell receptor (TCR) beta and gamma gene rearrangements in DNA extracted from available tissue samples.
Results: Among 112 patients, 61% (n=68) were male. Self-reported race was predominantly White or Caucasian (73.2%, n=82), followed by Black or African American (11.6%, n=12), and Asian (7.1%, n=8); remainder unknown. Most patients were non-Hispanic (73.2%, n=82). Median age at first and second lymphoma diagnosis was 63.5 (range, 18–86) and 67 (range, 19–88) years, respectively.
BCL was the first primary diagnosis in 66.7% (n=75) of patients, including large B-cell lymphoma (LBCL; 38.7%, n=29), follicular lymphoma (FL; 14.7%, n=11), marginal zone lymphoma (MZL; 14.7%, n=11), Hodgkin lymphoma (HL; 12%, n=9), and others (19.9%, n=15). Of those with first primary diagnosis of TCL (n=37), peripheral T-cell lymphoma (PTCL) accounted for 64.9% (n=24), including anaplastic large cell lymphoma (ALCL; 20.8%, n=5), angioimmunoblastic TCL (AITL; 20.8%, n=5), and others (58.4%, n=14), while cutaneous T-cell lymphoma accounted for 35.1% (n=13). In patients with second primary diagnosis of BCL (n=37), LBCL accounted for 40.5% (n=15), followed by FL (18.9%, n=7), MZL (8.1%, n=3), HL (8.1%, n=3), and others (24.4%, n=9), while second primary diagnosis of TCL (n=75) was most frequently PTCL in 80% (n=60), including AITL (36.1%, n=13), ALCL (30.6%, n=11) and others (33.3%, n=12). TCR rearrangement analysis was performed in most tissue samples of TCL (72.3%, n=81), demonstrating T-cell clonality in 80.3% (n=65).
NLMs occurred in 37.5% (n=42) of the cohort, with 35.7% (n=15) of affected patients developing more than one NLM. Non-melanoma skin cancers were the most common NLM, accounting for 52.4% (n=22), including basal cell carcinoma (BCC; 36.4%, n=8), squamous cell carcinoma (SCC; 36.4%, n=8), and both BCC and SCC (27.2%, n=6). Myeloid neoplasms accounted for 11.9% (n=5) of reported NLMs, whereas other solid malignancies occurred in 57.1% (n=24) of patients with NLMs. The most common solid malignancies were prostate carcinoma (30.7%, 8/26), breast carcinoma (19.2%, 5/26), and head and neck cancer (15.4%, 4/26).
Autoimmune comorbidities were present in 15.2% (n=17) of the cohort, most commonly rheumatoid arthritis (35.3%, n=6), psoriasis (23.5%, n=4), and Sjögren's syndrome (11.8%, n=2). A family history of autoimmune disorders was reported in 2.7% (n=3) of patients, while a family history of hematologic malignancies was positive in 16.1% (n=18), with lymphoid neoplasms accounting for 77.8% (n=14). HIV serologies were negative in all patients, whereas Hepatitis C, Hepatitis B, and CMV seropositivity were identified in 1.2% (n=1), 11.5% (n=10), and 60.3% (n=35), respectively, of those with data available. EBV-ISH was positive in 13.8% (n=13) of BCL and 22.3% (n=21) of TCL tumors, with concurrent positivity in 4.2% (n=4) of those with data available (n=94).
Conclusion: Dual BCL and TCL diagnoses in patients were frequently associated with additional malignancies, autoimmune comorbidities, EBV positivity of tumors, and a family history of malignancy. These findings suggest underlying immune dysregulation as a potential shared predisposing factor in addition to common environmental and genetic susceptibilities. Further studies incorporating genomic and molecular analyses are required to explore the underlying mechanisms of dual B-cell and T-cell lymphomagenesis and potential bidirectional risk of lymphoid malignancies in this rare population.
DISCLOSURES
Chiara Adina Hummel, MD: No relevant conflicts of interest to declare.